Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway

Purpose The mechanism of sodium–glucose cotransporter-2 inhibitor (SGLT-2i) reducing the incidence of atrial fibrillation remains unclear. We hypothesize that sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway. Methods A total of 42 rats were randomly assigned into three groups: control group (CON group); diabetes group (DM group): diabetes mellitus rats were established by 65 mg/kg streptozotocin (STZ) intraperitoneal injection; and diabetes + dapagliflozin group (DM + DAPA group): diabetic rats were given DAPA gavage administration (DAPA 2mg/kg/d for 4 weeks by gavage administration), 14 rats in each group. Epicardial multiple-lead recording and intracardiac electrophysiology studies were performed to investigate the electrical remodeling in the heart and the atrial fibrillation inducibility in each group. Western blot analysis and real-time PCR were used to determine the protein and mRNA expression of toll-like receptor 4 (TLR4), interleukin receptor-associated kinase 1 (IRAK1), tumor necrosis factor receptor-associated factor 6 (TRAF6), nuclear factor-kappa B (NF-κB), and type I collagen (collagen I). Results Compared with rats in CON group, rats in DM group showed marked myocardial fibrosis, ectopic pacing excitement, reduced conduction velocity, decreased cardiac function. TLR4/IRAK1/TRAF6/NF-κB, collagen I proteins expressions and incidence of atrial fibrillation (27.3%) were increased in DM group. Parts of these changes were reversed by treatment of DAPA. Incidence of atrial fibrillation was decreased in DM + DAPA group (2.8%). Conclusions SGLT-2i dapagliflozin may prevent diabetic rats' atrial remodeling and reduce the inducibility of atrial fibrillation partly by targeting TLR4/IRAK1/TRAF6/NF-κB inflammatory pathway.

[1]  Yan He,et al.  Silencing of TLR4 Inhibits Atrial Fibrosis and Susceptibility to Atrial Fibrillation via Downregulation of NLRP3-TGF-β in Spontaneously Hypertensive Rats , 2022, Disease markers.

[2]  E. Abdollahi,et al.  Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. , 2022, European journal of pharmacology.

[3]  Chao Yang,et al.  The Imbalance of MMP-2/TIMP-2 and MMP-9/TIMP-1 Contributes to Collagen Deposition Disorder in Diabetic Non-Injured Skin , 2021, Frontiers in Endocrinology.

[4]  Tsung-Ming Lee,et al.  Dapagliflozin attenuates arrhythmic vulnerabilities by regulating connexin43 expression via the AMPK pathway in post-infarcted rat hearts. , 2021, Biochemical pharmacology.

[5]  Jinyu Pan,et al.  Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats , 2021, Journal of cellular and molecular medicine.

[6]  P. Muszyński,et al.  Mitochondrial Dysfunction in Atrial Fibrillation—Mechanisms and Pharmacological Interventions , 2021, Journal of clinical medicine.

[7]  D. Matthews,et al.  Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis , 2021, Diabetes, obesity & metabolism.

[8]  C. Liang,et al.  Sodium–Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK–mTOR Signaling Pathway–Mediated Autophagy , 2021, Frontiers in Pharmacology.

[9]  Shih‐Ann Chen,et al.  Toll-like receptor 4 activation modulates pericardium-myocardium interactions in lipopolysaccharide-induced atrial arrhythmogenesis. , 2021, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  D. Newby,et al.  Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure , 2021, Heart.

[11]  Junyu Huo,et al.  Cardioprotection of Sodium–Glucose Cotransporter 2 Inhibition in Rats With Isoproterenol-Induced Cardiomyopathy , 2021 .

[12]  D. Giugliano,et al.  Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes , 2021, Cardiovascular Diabetology.

[13]  A. Pourbagheri-Sigaroodi,et al.  The role of toll‐like receptor 4 (TLR4) in cancer progression: A possible therapeutic target? , 2020, Journal of cellular physiology.

[14]  Xianhui Zhou,et al.  Apelin Inhibits Angiotensin II-Induced Atrial Fibrosis and Atrial Fibrillation via TGF-β1/Smad2/α-SMA Pathway , 2020, Frontiers in Physiology.

[15]  Chung‐Han Ho,et al.  Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients , 2020, Archives of toxicology.

[16]  L. Altucci,et al.  The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin , 2020, Cardiovascular Diabetology.

[17]  C. Zheng,et al.  Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection , 2020, International journal of molecular sciences.

[18]  G. Botti,et al.  NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells , 2020, International journal of molecular sciences.

[19]  D. Cummings,et al.  SGLT-2i and Atrial Fibrillation in the Cardiovascular and Renal Outcome Trials. , 2020, Diabetes, obesity & metabolism.

[20]  J. Pedraza-Chaverri,et al.  Mitochondrial dysfunction and endoplasmic reticulum stress in the promotion of fibrosis in obstructive nephropathy induced by unilateral ureteral obstruction , 2020, BioFactors.

[21]  S. Cabaro,et al.  Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes , 2020, Frontiers in Oncology.

[22]  H. Ozaki,et al.  Increased Blood Pressure Causes Lymphatic Endothelial Dysfunction via Oxidative Stress in Spontaneously Hypertensive Rats , 2020, Hypertension.

[23]  H. Lum,et al.  MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy , 2020, Nature Communications.

[24]  Y. Birnbaum,et al.  Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay , 2020, Cardiovascular Drugs and Therapy.

[25]  E. Braunwald,et al.  Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[26]  G. Bakris,et al.  Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure , 2020, European journal of heart failure.

[27]  D. Freimark,et al.  Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy , 2020, Cardiovascular Diabetology.

[28]  Yi-Han Chen,et al.  Cold-inducible RNA-binding protein modulates atrial fibrillation onset by targeting multiple ion channels. , 2020, Heart rhythm.

[29]  Shulin Wu,et al.  Mechanism of electrical remodeling of atrial myocytes and its influence on susceptibility to atrial fibrillation in diabetic rats. , 2019, Life sciences.

[30]  G. Coukos,et al.  Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance , 2019, Nature Reviews Clinical Oncology.

[31]  J. Halperin,et al.  Atrial Fibrillation and Diabetes Mellitus: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[32]  R. Wijesurendra,et al.  Mechanisms of atrial fibrillation , 2019, Heart.

[33]  P. Mauri,et al.  Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin/trastuzumab-induced cardiac toxicity. , 2019, Cardiovascular research.

[34]  Yi‐Jen Chen,et al.  Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats , 2019, International journal of molecular sciences.

[35]  S. Blankenberg,et al.  Inflammation and fibrosis in murine models of heart failure , 2019, Basic Research in Cardiology.

[36]  A. Gillis,et al.  The Association Between Diabetes Mellitus and Atrial Fibrillation: Clinical and Mechanistic Insights , 2019, Front. Physiol..

[37]  T. Miura,et al.  Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats , 2019, Journal of diabetes investigation.

[38]  Li Li,et al.  Extracellular matrix remodeling and cardiac fibrosis. , 2018, Matrix biology : journal of the International Society for Matrix Biology.

[39]  The Lancet Oncology.  Immunotherapy: hype and hope. , 2018, The Lancet. Oncology.

[40]  J. McMurray,et al.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.

[41]  R. Coronel,et al.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation , 2017, Diabetologia.

[42]  B. Carstensen,et al.  Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study , 2017, Diabetes, obesity & metabolism.

[43]  Tsung-Ming Lee,et al.  Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts , 2017, Free radical biology & medicine.

[44]  S. Jiang,et al.  The emerging role of Toll-like receptor 4 in myocardial inflammation , 2016, Cell Death and Disease.

[45]  M. Roncaglioni,et al.  Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. , 2015, Diabetes research and clinical practice.

[46]  Z. Sepehri,et al.  Human Toll like receptor 4 gene expression of PBMCs in diabetes mellitus type 2 patients. , 2015, Cellular and molecular biology.

[47]  Jian Li,et al.  Probucol Prevents Atrial Remodeling by Inhibiting Oxidative Stress and TNF‐α/NF‐κB/TGF‐β Signal Transduction Pathway in Alloxan‐Induced Diabetic Rabbits , 2015, Journal of cardiovascular electrophysiology.

[48]  T. Münzel,et al.  The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity , 2014, PloS one.

[49]  Jie Yang,et al.  Emodin attenuates high glucose-induced TGF-β1 and fibronectin expression in mesangial cells through inhibition of NF-κB pathway. , 2013, Experimental cell research.

[50]  Jeffrey Bartholet,et al.  Hype and hope. , 2013, Scientific American.

[51]  C. Pollock,et al.  Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy? , 2013, PloS one.

[52]  Eric Verdin,et al.  Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor , 2013, Science.

[53]  T. Chao,et al.  Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. , 2012, International journal of cardiology.

[54]  Yan Li,et al.  Myocardial Ischemia Activates an Injurious Innate Immune Signaling via Cardiac Heat Shock Protein 60 and Toll-like Receptor 4* , 2011, The Journal of Biological Chemistry.

[55]  T. Lawrence.  The nuclear factor NF-kappaB pathway in inflammation. , 2009, Cold Spring Harbor perspectives in biology.

[56]  Zhu Jianhua,et al.  Gap junction and Na+-H+ exchanger alternations in fibrillating and failing atrium. , 2008, International journal of cardiology.

[57]  O. Hurtado,et al.  Toll-Like Receptor 4 Is Involved in Brain Damage and Inflammation After Experimental Stroke , 2007, Circulation.

[58]  K. Miyake,et al.  Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[59]  G. Troncone,et al.  Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development , 2005, Oncogene.

[60]  G. Troncone,et al.  Overexpression of the ped/pea-15 Gene Causes Diabetes by Impairing Glucose-Stimulated Insulin Secretion in Addition to Insulin Action , 2004, Molecular and Cellular Biology.

[61]  Shizuo Akira,et al.  TLR signaling pathways. , 2004, Seminars in immunology.

[62]  Junyu Huo,et al.  The cardioprotective effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in rats with isoproterenol-induced cardiomyopathy. , 2021, American journal of translational research.

[63]  P. Olinga,et al.  Targeting Oxidative Stress for the Treatment of Liver Fibrosis. , 2018, Reviews of physiology, biochemistry and pharmacology.

[64]  J. Tong,et al.  Up-regulation of Toll-like receptor 4/nuclear factor-kappaB signaling is associated with enhanced adipogenesis and insulin resistance in fetal skeletal muscle of obese sheep at late gestation. , 2010, Endocrinology.